A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

Clinical Trial

NCT04270747 Completed

A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects With Neovascular Age-related Macular Degeneration

Phase 3

Interventional

Disease

Disease type

Other

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

22/06/2020

Closing date

18/07/2022

Inclusion criteria :

Exclusion criteria :

Funding

private

Members involved

Others investigators

Dr Mikk Pauklin

Representative

Estonia

Anterior Segment Rare Eye Diseases (WG4)

Dr Laura Mauring

Substitute

Estonia

Genetic Diagnostics (TWG6), Pediatric Ophthalmology Rare Diseases (WG3), Retinal Rare Eye Diseases (WG1)

Dr Artur Klett

Representative

Estonia

Anterior Segment Rare Eye Diseases (WG4), National Integration (TWG9)

Dr Kristel Harak

Estonia

Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Registries & Epidemiology (TWG7), Retinal Rare Eye Diseases (WG1)

Pr Paul Friedemann

Representative

Germany

Neuro-Ophthalmology Rare Diseases (WG2), Registries & Epidemiology (TWG7), Research (TWG8)

Pr Daniel Böhringer

Representative

Germany

Anterior Segment Rare Eye Diseases (WG4)

Working Group Leader

Pr Julian Garcia Feijoo

Representative

Spain

CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8)